Jorge B L Cannata-AndÃ-a

List of Publications by Year
in descending order

204 papers	12,085 citations	25034 57 h-index	28297 105 g-index
211 all docs	211 docs citations	211 times ranked	10866 citing authors

#	Article	IF	Citations
1	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. New England Journal of Medicine, 2004, 350, 459-468.	27.0	1,465
2	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.7	628
3	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2012, 307, 674.	7.4	495
4	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 4263-4272.	0.7	460
5	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2003, 14, 19-26.	3.1	251
6	Large-Scale Analysis of Association Between <emph type="ital">LRP5</emph> and <emph type="ital">LRP6</emph> Variants and Osteoporosis. JAMA - Journal of the American Medical Association, 2008, 299, 1277.	7.4	246
7	Nutritional status in dialysis patients: a European consensus. Nephrology Dialysis Transplantation, 2002, 17, 563-572.	0.7	206
8	Mortality Associated with Vertebral Deformity in Men and Women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 1998, 8, 291-297.	3.1	197
9	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2002, 13, 565-571.	3.1	191
10	Osteoporosis in chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 566-571.	1.9	189
11	Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney International, 2008, 74, 1070-1078.	5.2	183
12	Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study. Journal of Bone and Mineral Research, 1997, 12, 1883-1894.	2.8	177
13	Validity of Self-Report of Fractures: Results from a Prospective Study in Men and Women Across Europe. Osteoporosis International, 2000, 11, 248-254.	3.1	177
14	Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporosis International, 2008, 19, 1161-1166.	3.1	169
15	Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrology Dialysis Transplantation, 2002, 17, 723-731.	0.7	162
16	Health-related quality of life and radiographic vertebral fracture. Osteoporosis International, 2004, 15, 113-119.	3.1	161
17	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2001, 12, 85-90.	3.1	159
18	Population-based geographic variations in dxa bone density in Europe: The evos study. Osteoporosis International, 1997, 7, 175-189.	3.1	148

#	Article	IF	Citations
19	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.7	140
20	SYSTEMIC ALUMINUM TOXICITY: EFFECTS ON BONE, HEMATOPOIETIC TISSUE, AND KIDNEY. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1996, 48, 649-666.	2.3	137
21	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrology Dialysis Transplantation, 2010, 25, 2846-2850.	0.7	137
22	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	5.2	136
23	The Effects of Lifestyle, Dietary Dairy Intake and Diabetes on Bone Density and Vertebral Deformity Prevalence: The EVOS Study. Osteoporosis International, 2001, 12, 688-698.	3.1	135
24	Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrology Dialysis Transplantation, 2011, 26, 1938-1947.	0.7	133
25	Vascular Calcifications. Journal of the American Society of Nephrology: JASN, 2006, 17, S267-S273.	6.1	131
26	High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone, 2010, 46, 121-128.	2.9	127
27	Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. International Journal of Molecular Sciences, 2021, 22, 408.	4.1	125
28	Direct inhibition of osteoblastic Wnt pathway byÂfibroblast growth factor 23 contributes toÂboneÂloss in chronic kidney disease. Kidney International, 2016, 90, 77-89.	5.2	120
29	Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 2008, 24, 239-246.	0.7	118
30	The connections between vascular calcification and bone health. Nephrology Dialysis Transplantation, 2011, 26, 3429-3436.	0.7	116
31	Reproducibility of a Questionnaire on Risk Factors for Osteoporosis in a Multicentre Prevalence Survey: The European Vertebral Osteoporosis Study. International Journal of Epidemiology, 1994, 23, 559-565.	1.9	113
32	Cancer-associated bone disease. Osteoporosis International, 2013, 24, 2929-2953.	3.1	113
33	The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporosis International, 2003, 14, 520-524.	3.1	112
34	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American Heart Journal, 2012, 164, 902-909.e2.	2.7	112
35	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporosis International, 2004, 15, 760-765.	3.1	106
36	Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. Kidney International, 2003, 63, S44-S48.	5.2	95

#	Article	IF	Citations
37	Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current Medical Research and Opinion, 2003, 19, 383-394.	1.9	94
38	Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: The GENOMOS study. Bone, 2008, 42, 969-981.	2.9	91
39	Indirect Regulation of PTH by Estrogens May Require FGF23. Journal of the American Society of Nephrology: JASN, 2009, 20, 2009-2017.	6.1	89
40	Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone, 2005, 36, 387-398.	2.9	88
41	Erythropoietin in chronic renal failure. Kidney International, 1996, 50, 1373-1391.	5.2	83
42	The position of strontium ranelate in todayâ€™s management of osteoporosis. Osteoporosis International, 2015, 26, 1667-1671.	3.1	81
43	Survey response rates: national and regional differences in a European multicentre study of vertebral osteoporosis.. Journal of Epidemiology and Community Health, 1995, 49, 87-93.	3.7	79
44	COSMOS: the dialysis scenario of CKDâ€“MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.7	79
45	The clinical impact of aluminium overload in renal failure. Nephrology Dialysis Transplantation, 2002, 17, 9-12.	0.7	78
46	Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrology Dialysis Transplantation, 2014, 29, 1415-1422.	0.7	74
47	MicroRNAs 29b, 133b, and 211 Regulate Vascular Smooth Muscle Calcification Mediated by High Phosphorus. Journal of the American Society of Nephrology: JASN, 2016, 27, 824-834.	6.1	71
48	Chronic Kidney Diseaseâ€”Mineral and Bone Disorders: Pathogenesis and Management. Calcified Tissue International, 2021, 108, 410-422.	3.1	71
49	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. Nephrology Dialysis Transplantation, 2013, 28, 2940-2945.	0.7	70
50	Management of osteoporosis in the elderly. Current Medical Research and Opinion, 2009, 25, 2373-2387.	1.9	69
51	The influence of family history of hip fracture on the risk of verterbral deformity in men and women: The European vertebral osteoporosis study. Bone, 1997, 20, 145-149.	2.9	65
52	Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney International, 1991, 39, 799-803.	5.2	64
53	EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 310-320.	6.1	63
54	Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2008, 23, 3731-3737.	0.7	62

#	Article	IF	Citations
55	Necrotic Concentrations of Cisplatin Activate the Apoptotic Machinery but Inhibit Effector Caspases and Interfere with the Execution of Apoptosis. Toxicological Sciences, 2011, 122, 73-85.	3.1	60
56	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrology Dialysis Transplantation, 2008, 23, 2162-2166.	0.7	59
57	Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrology Dialysis Transplantation, 2013, 28, 2735-2744.	0.7	59
58	Adynamic Bone and Chronic Renal Failure: An Overview. American Journal of the Medical Sciences, 2000, 320, 81-84.	1.1	56
59	Reference Values for Trace and Ultratrace Elements in Human Serum Determined by Double-Focusing ICP-MS. Biological Trace Element Research, 2001, 82, 259-272.	3.5	55
60	Photoacoustic Imaging With a Commercial Ultrasound System and a Custom Probe. Ultrasound in Medicine and Biology, 2011, 37, 484-492.	1.5	53
61	Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Annals of the Rheumatic Diseases, 2008, 67, 1736-1738.	0.9	52
62	Vitamin D Receptor Gene Polymorphisms, Bone Mass, Bone Loss and Prevalence of Vertebral Fracture: Differences in Postmenopausal Women and Men. Osteoporosis International, 1999, 10, 175-182.	3.1	50
63	Osteoporosis and adynamic bone in chronic kidney disease. Journal of Nephrology, 2013, 26, 73-80.	2.0	50
64	Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrology Dialysis Transplantation, 2008, 23, 3479-3484.	0.7	49
65	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	4.5	49
66	Hypokinetic azotemic osteodystrophy. Kidney International, 1998, 54, 1000-1016.	5.2	48
67	Falls explain between-center differences in the incidence of limb fracture across Europe. Bone, 2002, 31, 712-717.	2.9	47
68	Atomic spectrometric methods (atomic absorption and inductively coupled plasma atomic emission) for the determination of aluminium at the parts per billion level in biological fluids. Journal of Analytical Atomic Spectrometry, 1987, 2, 177.	3.0	46
69	Height and body mass index in oslo, norway, compared to other regions of europe: do they explain differences in the incidence of hip fracture?. Bone, 1995, 17, 347-350.	2.9	46
70	Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Current Medical Research and Opinion, 2007, 23, 3041-3045.	1.9	46
71	Effect of aluminium load on parathyroid hormone synthesis. Nephrology Dialysis Transplantation, 2001, 16, 742-745.	0.7	42
72	The challenge of controlling phosphorus in chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 541-547.	0.7	42

#	Article	IF	Citations
73	High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 934-941.	0.7	42
74	Role of the RANK/RANKL/OPG and Wnt/Î²-Catenin Systems in CKD Bone and Cardiovascular Disorders. Calcified Tissue International, 2021, 108, 439-451.	3.1	41
75	Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporosis International, 2005, 16, 2013-2017.	3.1	40
76	Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. Nephrology Dialysis Transplantation, 2017, 32, 1831-1840.	0.7	40
77	Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. Nephrology Dialysis Transplantation, 2002, 17, 1875-1878.	0.7	39
78	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrologia, 2011, 31 Suppl 1, 3-32.	0.4	37
79	Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease. American Journal of Nephrology, 2011, 33, 139-149.	3.1	36
80	Mechanisms of aluminum-induced microcytosis: Lessons from accidental aluminum intoxication. Kidney International, 1995, 47, 164-168.	5.2	35
81	High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine. Clinica Chimica Acta, 1990, 189, 69-79.	1.1	34
82	Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrology Dialysis Transplantation, 2002, 17, 16-19.	0.7	34
83	Renal amyloidosis in familial Mediterranean fever. Kidney International, 2004, 65, 1118-1127.	5.2	34
84	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2006, 17, 1369-1381.	3.1	34
85	A new role for vitamin D receptor activation in chronic kidney disease. American Journal of Physiology - Renal Physiology, 2009, 297, F1502-F1509.	2.7	32
86	Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. Medicine (United States), 2015, 94, e1218.	1.0	31
87	A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-Dâ€"a randomised multicentre international clinical trial. BMC Medicine, 2022, 20, 83.	5.5	31
88	A comparison of albumin, polygeline and crystalloid priming solutions for cardiopulmonary bypass in patients having coronary artery bypass graft surgery. Perfusion (United Kingdom), 1995, 10, 415-424.	1.0	30
89	Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: Evidence for an association to haplogroup H. Mitochondrion, 2011, 11, 176-181.	3.4	29
90	Low calcidiol levels and risk of progression of aortic calcification. Osteoporosis International, 2012, 23, 1177-1182.	3.1	29

#	Article	IF	Citations
91	Influence of polymorphisms in VDR and COLIA1 genes on the risk of osteoporotic fractures in aged men. Kidney International, 2003, 63, S14-S18.	5.2	28
92	Prevention of aluminium exposure through dialysis fluids. Analysis of changes in the last 8 years. Nephrology Dialysis Transplantation, 1998, 13, 78-81.	0.7	27
93	Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoporosis (NEMO). Bone, 2007, 40, 662-673.	2.9	27
94	Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrologia, 2013, 33, 46-60.	0.4	27
95	Effects of calcitriol and paricalcitol on renal fibrosis in CKD. Nephrology Dialysis Transplantation, 2021, 36, 793-803.	0.7	26
96	Prevalence of osteoporosis in men and determinants of changes in bone mass in a non-selected Spanish population. Osteoporosis International, 2005, 16, 603-609.	3.1	25
97	Childhood Fractures Do Not Predict Future Fractures: Results From the European Prospective Osteoporosis Study. Journal of Bone and Mineral Research, 2009, 24, 1314-1318.	2.8	25
98	Different Patterns of Renal Osteodystrophy in Iberoamerica. American Journal of the Medical Sciences, 2000, 320, 76-80.	1.1	24
99	Aluminum Exposure in Chronic Renal Failure in Iberoamerica at the End of the 1990s: Overview and Perspectives. American Journal of the Medical Sciences, 2000, 320, 96-99.	1.1	24
100	Chapter 1: Introduction and definition of CKDâ€“MBD and the development of the guideline statements. Kidney International, 2009, 76, S3-S8.	5.2	24
101	Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxido-reductase activity. Molecular and Biochemical Parasitology, 2010, 173, 132-141.	1.1	24
102	Aluminum-Induced Osteogenesis in Osteopenic Rats with Normal Renal Function. Calcified Tissue International, 1999, 64, 534-541.	3.1	23
103	Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrology Dialysis Transplantation, 2010, 25, 2930-2937.	0.7	23
104	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.7	23
105	Binding of aluminium to plasma proteins: Comparative effect of desferrioxamine and deferiprone (L1). Clinica Chimica Acta, 1994, 230, 137-145.	1.1	22
106	Epidemiology of renal osteodystrophy in Iberoamerica. Nephrology Dialysis Transplantation, 1998, 13, 41-45.	0.7	22
107	Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. Kidney International, 2005, 67, 2267-2279.	5.2	22
108	Calcium in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, S1-S2.	4.5	22

#	Article	IF	Citations
109	Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrology Dialysis Transplantation, 1998, 13, 1538-1542.	0.7	21
110	Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a caseâ€“control study in a Spanish population. Coronary Artery Disease, 2009, 20, 383-386.	0.7	21
111	Differential effects of 17Î²-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. Menopause, 2010, 17, 766-771.	2.0	21
112	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). Journal of Nephrology, 2008, 21, 290-8.	2.0	21
113	Effects of Menstrual History and Use of Medications on Bone Mineral Density: The EVOS Study. Calcified Tissue International, 1998, 63, 271-276.	3.1	20
114	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clinical Trials, 2011, 8, 165-174.	1.6	20
115	Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification. Osteoporosis International, 2014, 25, 1237-1246.	3.1	20
116	Reconsidering the Importance of Longâ€Term Lowâ€Level Aluminum Exposure in Renal Failureâ€ƒPatients. Seminars in Dialysis, 2001, 14, 5-7.	1.3	19
117	A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms. Journal of Molecular Endocrinology, 2003, 31, 255-262.	2.5	19
118	The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. CKJ: Clinical Kidney Journal, 2008, 1, i2-i6.	2.9	19
119	Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis. Medical Principles and Practice, 2011, 20, 203-212.	2.4	19
120	Vertebral Scheuermannâ€™s disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Osteoporosis International, 2015, 26, 2509-2519.	3.1	19
121	Chronic kidney disease--mineral and bone disorder: a complex scenario. Nefrologia, 2011, 31, 514-9.	0.4	19
122	Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?. Nutrients, 2021, 13, 3835.	4.1	19
123	Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure. Kidney International, 2003, 63, S39-S43.	5.2	18
124	PATHOGENESIS OF BONE AND MINERAL RELATED DISORDERS IN CHRONIC KIDNEY DISEASE: KEY ROLE OF HYPERPHOSPHATEMIA. Journal of Renal Care, 2009, 35, 34-38.	1.2	18
125	Natural antioxidants and vascular calcification: a possible benefit. Journal of Nephrology, 2011, 24, 669-672.	2.0	18
126	Phosphorus and Survival. Journal of the American Society of Nephrology: JASN, 2009, 20, 234-236.	6.1	17

#	Article	IF	Citations
127	H 2 O 2 Regulation of Vascular Function Through sGC mRNA Stabilization by HuR. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 567-573.	2.4	17
128	Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity. Nephrology Dialysis Transplantation, 1998, 13, 23-28.	0.7	16
129	Aluminium removal with the double chamber technique: paired filtration-dialysis (PFD). Nephrology Dialysis Transplantation, 1998, 13, 82-87.	0.7	16
130	Response of parathyroid glands to calcitriol in culture: Is this response mediated by the genetic polymorphisms in vitamin D receptor?. Kidney International, 2003, 63, S19-S22.	5.2	16
131	Aluminum posttranscriptional regulation of parathyroid hormone synthesis: A role for the calcium-sensing receptor. Kidney International, 2005, 68, 2484-2496.	5.2	16
132	Barley-ÃŸ-glucans reduce systemic inflammation, renal injury and aortic calcification through ADAM17 and neutral-sphingomyelinase2 inhibition. Scientific Reports, 2019, 9, 17810.	3.3	16
133	Prevention, diagnosis and treatment of renal osteodystrophy in Spain. Preliminary results from a multicentre enquiry. Nephrology Dialysis Transplantation, 1998, 13, 51-56.	0.7	15
134	Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy. Bone, 2007, 41, 614-619.	2.9	15
135	Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats. Endocrinology, 2012, 153, 1627-1637.	2.8	15
136	Micellar versus reversed phase liquid chromatography for the determination of desferrioxamine and its chelates with aluminium and iron in uremic serum. Talanta, 1997, 45, 25-33.	5.5	14
137	Lack of Association between Endothelin-1 Gene Variants and Myocardial Infarction. Journal of Atherosclerosis and Thrombosis, 2009, 16, 388-395.	2.0	14
138	Pathogenesis, prevention and management of low-bone turnover. Nephrology Dialysis Transplantation, 2000, 15, 15-17.	0.7	13
139	Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts. Kidney International, 2003, 63, S23-S27.	5.2	13
140	New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. Molecular Biology Reports, 2012, 39, 8777-8785.	2.3	13
141	Variants in cardiac <scp>GATA</scp> genes associated with bicuspid aortic valve. European Journal of Clinical Investigation, 2018, 48, e13027.	3.4	13
142	The receptor activator of nuclear factor Î¹Î' ligandÂreceptor leucine-rich repeat-containing G-protein-coupled receptor 4Âcontributes to parathyroid hormone-induced vascular calcification. Nephrology Dialysis Transplantation, 2021, 36, 618-631.	0.7	13
143	The influence of transpulmonary pressure on the diameter of small arterial blood vessels in the lung. Microvascular Research, 1976, 11, 57-66.	2.5	12
144	Vitamin D receptor gene (VDR) polymorphisms: effect on bone mass, bone loss and parathyroid hormone regulation. Nephrology Dialysis Transplantation, 1998, 13, 73-77.	0.7	11

#	Article	IF	Citations
145	Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation. World Journal of Urology, 2009, 27, 787-797.	2.2	11
146	Estrogens and bone disease in chronic kidney disease: role of FGF23. Current Opinion in Nephrology and Hypertension, 2010, 19, 354-358.	2.0	11
147	An improved wave-vector frequency-domain method for nonlinear wave modeling. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2014, 61, 515-524.	3.0	11
148	Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis. Scientific Reports, 2019, 9, 2546.	3.3	11
149	Management of Secondary Hyperparathyroidism: The Gap between Diagnosis and Treatment. American Journal of the Medical Sciences, 2000, 320, 107-111.	1.1	10
150	2010 - GuÃa de prÃ¡ctica clÃnica de la Sociedad EspaÃ±ola de DiÃ¡lisis y Trasplante de las alteraciones del metabolismo mineral y Ã³seo de la enfermedad renal crÃ³nica (CKD-MBD). Dialisis Y Trasplante, 2011, 32, 108-118.	0.4	9
151	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Modern Pathology, 2011, 24, 698-707.	5.5	9
152	Amadori products promote cellular senescence activating insulin-like growth factor-1 receptor and down-regulating the antioxidant enzyme catalase. International Journal of Biochemistry and Cell Biology, 2013, 45, 1255-1264.	2.8	9
153	A subset of low density granulocytes is associated with vascular calcification in chronic kidney disease patients. Scientific Reports, 2019, 9, 13230.	3.3	9
154	Long-term response of cultured rat parathyroid glands to calcium and calcitriol: the effect of cryopreservation. Journal of Nephrology, 2005, 18, 141-7.	2.0	9
155	New therapies: calcimimetics, phosphate binders and vitaminÂD receptor activators. Pediatric Nephrology, 2010, 25, 609-616.	1.7	8
156	Supplementation of vitamin D and calcium: advantages and risks**Reference of original article: Jackson RD et al. Calcium plus Vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669â€“683.. Nephrology Dialysis Transplantation, 2006, 21, 2375-2377.	0.7	7
157	Viability and Functionality of Fresh and Cryopreserved Human Hyperplastic Parathyroid Tissue Tested in vitro. American Journal of Nephrology, 2008, 28, 76-82.	3.1	7
158	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2009, 2, 213-221.	2.9	7
159	Should cinacalcet be used in patients who are not on dialysis?. Nature Reviews Nephrology, 2009, 5, 307-308.	9.6	7
160	Low transcriptional activity haplotype of matrix metalloproteinase 1 is less frequent in bicuspid aortic valve patients. Gene, 2013, 524, 304-308.	2.2	7
161	The hypercalcaemia of CYP24A1 inactivation: new ways to improve diagnosis and treatment: Fig.Â1.. CKJ: Clinical Kidney Journal, 2015, 8, 456-458.	2.9	7
162	Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study. CKJ: Clinical Kidney Journal, 2021, 14, 1770-1779.	2.9	7

#	Article	IF	Citations
163	REGIONAL VASCULAR RESPONSE TO HYPOXIA IN THE LUNGS OF ANAESTHETISED SHEEP. The Australian Journal of Experimental Biology and Medical Science, 1974, 52, 801-812.	0.7	6
164	Exploratory investigations on the potential of radiofrequency glow discharge-optical emission spectrometry for the direct elemental analysis of bone. Journal of Analytical Atomic Spectrometry, 2001, 16, 250-255.	3.0	6
165	Bicuspid aortic valve syndrome: A heterogeneous and still unknown condition. International Journal of Cardiology, 2014, 177, 1105.	1.7	6
166	Rare Genetic Variants in Gata Transcription Factors in Patients with Hypertrophic Cardiomyopathy. Journal of Investigative Medicine, 2017, 65, 926-934.	1.6	6
167	Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration. American Journal of Kidney Diseases, 2000, 36, 969-975.	1.9	5
168	Proyecto COSMOS: escenario de la hemodiÃ¡lisis en Europa. Nefrologia, 2016, 36, 381-388.	0.4	5
169	Time course and functional correlates of post-transplant aluminium elimination. Nephrology Dialysis Transplantation, 1998, 13, 98-102.	0.7	4
170	Updated programme for harmonization of training in nephrology in the European Union. CKJ: Clinical Kidney Journal, 2013, 6, 116-121.	2.9	4
171	Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease. Seminars in Dialysis, 2015, 28, 587-593.	1.3	4
172	What should the characteristics and attributes of an accredited nephrology training programme be? Looking for high standards: Table 1.. CKJ: Clinical Kidney Journal, 2016, 9, 23-28.	2.9	4
173	Changing the current terminology in medicine--Always a challenge. Nephrology Dialysis Transplantation, 2007, 22, 1811-1812.	0.7	3
174	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.4	3
175	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.4	3
176	Influencia de la sobrecarga de calcio sobre el metabolismo Ã³seo y mineral en 55 centros de hemodiÃ¡lisis de Lima. Nefrologia, 2018, 38, 279-285.	0.4	3
177	The European Certificate in Nephrology: towards harmonization and excellence in training. CKJ: Clinical Kidney Journal, 2019, 12, 167-171.	2.9	3
178	Renal osteodystrophy in Iberoamerica. American Journal of Kidney Diseases, 1999, 34, lviii-lx.	1.9	2
179	Iron Deficiency and Intestinal Aluminium Absorption: Implications for Erythropoietin and Deferoxamine Therapy. Seminars in Dialysis, 1991, 4, 224-226.	1.3	2
180	Osteoporosis therapyâ€"time to consider renal function. Nature Reviews Endocrinology, 2011, 7, 440-441.	9.6	2

#	Article	IF	Citations
181	COSMOS Project: Haemodialysis scenario in Europe. Nefrologia, 2016, 36, 381-388.	0.4	2
182	Mineral and Bone Disorders in Chronic Kidney Disease. , 2014, , 223-239.		2
183	Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure. Nefrologia, 2021, 41, 640-651.	0.4	2
184	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction. Nefrologia, 2011, 31 Suppl 1, 1-2.	0.4	2
185	REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. Nefrologia, 2014, 34, 360-8.	0.4	2
186	Bone Aluminum Uptake in Uremic Rats Receiving Intraperitoneal Iron. Biological Trace Element Research, 2001, 84, 129-137.	3.5	1
187	Residue 826 in the Calcium-Sensing Receptor Is Implicated in the Response to Calcium and to R-568 Calcimimetic Compound. Calcified Tissue International, 2010, 86, 227-233.	3.1	1
188	Parathyroid gland regulation: contribution of thein vivoandin vitromodels. Expert Opinion on Drug Discovery, 2010, 5, 265-275.	5.0	1
189	Aortic stenosis: A complex, atherosclerosis-like, multifactorial disease. International Journal of Cardiology, 2013, 168, 2966.	1.7	1
190	Clinical relevance and future perspective of fractures inÂpatients with chronic kidneyÂdisease. Kidney International, 2018, 93, 1248.	5.2	1
191	Vitamin D and Renal Disease. , 2018, , 445-469.		1
192	Impact of calcium overload on bone and mineral metabolism at 55 hemodialysis centers in Lima. Nefrologia, 2018, 38, 279-285.	0.4	1
193	The First European Renal Association-European Dialysis and Transplant Association CKD Anaemia Physician Behaviours Survey: key findings. Journal of Nephrology, 2008, 21, 190-6.	2.0	1
194	Spanish nephrologists and the management of mineral and bone metabolism disorders in chronic kidney disease. Nefrologia, 2014, 34, 175-88.	0.4	1
195	Renal Osteodystrophy: An Update. American Journal of the Medical Sciences, 2000, 320, 75.	1.1	0
196	Advances in Renal Osteodystrophyâ€" IV International Symposium. Kidney International, 2003, 63, S1.	5.2	0
197	Note from the ERA-EDTA. Nephrology Dialysis Transplantation, 2007, 23, 474-474.	0.7	0
198	ERA-EDTA--a dynamic association moving forward. Nephrology Dialysis Transplantation, 2008, 23, 3024-3025.	0.7	0

#	Article	IF	Citations
199	Comment on Freemantle et al.: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments. Osteoporosis International, 2013, 24, 1929-1930.	3.1	0
200	FP580MUSCLE STRENGTH, MUSCLE MASS AND ARTERIAL STIFFNESS IN PERITONEAL DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii267-iii267.	0.7	0
201	MP344THE INTERDIALYTIC PERIOD FOR BLOOD COLLECTION INFLUENCES SERUM PHOSPHORUS AND THE RISK OF MORTALITY IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2016, 31, i454-i454.	0.7	0
202	ContribuciÃ³n de fÃ³sforo y PTH al desarrollo de hipertrofia y fibrosis cardÃaca en un modelo experimental de insuficiencia renal crÃ³nica. Nefrologia, 2021, 41, 640-651.	0.4	0
203	FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
204	Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.	2.9	0